Get started
Author

Albert Pérez-Montaña

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
2019 · Juan-Jose Garcés, Michal Simicek, et al. · Leukemia · 70
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
2022 · Cristina Pascual Izquierdo, María Eva Mingot-Castellano, et al. · Blood Advances · 65
PDF
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2022 · Rosalinda Termini, David Žihala, et al. · Clinical Cancer Research · 55
PDF
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
2020 · on behalf of the GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Juan-José Garcés, et al. · Leukemia · 54
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
2023 · Cirino Botta, Cristina Perez, et al. · Nature Communications · 46
PDF
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies
2023 · Leire Burgos, Luis-Esteban Tamariz-Amador, et al. · Journal of Clinical Oncology · 34
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
2021 · Daniel Alameda, Ibai Goicoechea, et al. · Blood · 30
PDF
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
2018 · Noemi Puig, Bruno Paiva, et al. · Leukemia · 23
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
2020 · Isabel Cuenca, Daniel Alameda, et al. · Leukemia · 17
PDF
MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significance
2018 · Francisca Barceló, Rosa Gomila, et al. · PLoS ONE · 14
Identification of Two Novel EPOR Gene Variants in Primary Familial Polycythemia: Case Report and Literature Review
2022 · Laura Lo Riso, Gardenia Vargas-Parra, et al. · Genes · 7
Immune biomarkers of increased infection risk in multiple myeloma
2026 · Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, et al. · Blood · 5
Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)
2023 · Camila Guerrero, Rosalinda Termini, et al. · Blood · 2
Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study
2025 · Marta Lasa, Esperanza Martin-Sanchez, et al. · Blood · 1
PDF
Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features
2025 · Esperanza Martin-Sanchez, Marta Lasa, et al. · Blood · 1
Asociación temporal de linfoma de Hodgkin y linfoma no hodgkiniano: estudio de 6 pacientes en un solo centro
2012 · Albert Pérez-Montaña, Juan-Manuel Sancho, et al. · Medicina Clínica · 1
Remisión completa espontánea en dos pacientes con leucemia linfática crónica
2010 · Albert Pérez-Montaña, José-Tomás Navarro, et al. · Medicina Clínica · 1
Real-world evidence of measurable residual disease assessment in multiple myeloma
2025 · Maria-Teresa Cedena, Noemi Puig, et al. · Blood Advances
PDF
Immune biomarkers of increased risk of infection in multiple myeloma (MM)
2025 · Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, et al. · Blood
PDF
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023 · Rosalinda Termini, David Žihala, et al.
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023 · Rosalinda Termini, David Žihala, et al.
PDF
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023 · Rosalinda Termini, David Žihala, et al.
PDF
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023 · Rosalinda Termini, David Žihala, et al.
PDF
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023 · Rosalinda Termini, David Žihala, et al.
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023 · Rosalinda Termini, David Žihala, et al.
Works count: 58
Citation count: 426
H-index: 10
I10-index: 10
Year
Topic
Type